Abstract Background/Aims: Whether angiotensin converting enzyme inhibitors (ACE) and
angiotensin receptor blockers (ARB) are differentially associated with reductions in …

Long-term benefit of using a renin–angiotensin–aldosterone system blocker such as an
angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) …

To compare the relative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs) in reducing cardiovascular mortality in chronic …

Background: Cardiovascular disease is the leading cause of mortality among patients with
end-stage renal disease undergoing dialysis. Angiotensin-converting enzyme inhibitors …

Objectives: The study objective was to assess the association between angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in …

Background Angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor
blockers (ARBs) are recommended by guidelines as first-line antihypertensive therapies in …

Background It is controversial whether treatment with an angiotensin II receptor blocker
(ARB) or a calcium channel blocker (CCB) improves prognosis of hemodialysis (HD) …

Background The association between the use of angiotensin‐converting enzyme inhibitors
(ACEI) and angiotensin receptor blockers (ARB) and mortality in end‐stage renal disease …

BACKGROUND: Persons with end-stage renal disease (ESRD) on hemodialysis carry an
exceptionally high burden of cardiovascular disease. Angiotensin-converting enzyme …

Background The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) reducing risk of cardiovascular events (CVEs) and preserving …